University of Thessaly (UTH)
Ο επιπολασμός και το κόστος της χρόνιας αποφρακτικής πνευμονοπάθειας
Abstract
dc:descriptionIntroduction: COPD is a chronic disease whose progression and natural course is affected by many factors, while it places a major burden on healthcare systems and has substantial social and economic effects.Objective: The objective of the study was to investigate the epidemiological and clinical characteristics of COPD patients and the potential risk factors associated with the progression and natural course of the disease. Additionally, an estimation of the annual direct cost of stable COPD was attempted, also analyzed per disease stage and per patient’s or payer’s perspective. Study Population and Methods: Data were collected from 245 COPD patients (males: 94.3%, mean age: 69.5 ± 8.8 years) who visited the outpatient units of the University Hospital of Larissa from 1/1/2014 to 31/12/2015 . Each patient performed pulmonary function test, while medical history was taken and physical examination was performed. Moreover, the patients’ direct cost during the maintenance phase was calculated, by recording the use of healthcare services during the maintenance phase in the 12 months prior to patient’s enrollment. Cost estimates were conducted using bottom-up approach and costs were calculated as mean values per patient, in Euros. Statistical analysis was performed using SPSS v. 20.Results: COPD patients were 11% of Stage I, 48.2% of Stage II, 29% of Stage III, and 11.8% of Stage IV, while according to GOLD 2016 groups the patients were 23.3% group A, 15.5% / group B, 22.9% / group C and 38.4% / group D. There was a significant proportion of current smokers (44,9%) and an increased use of healthcare services by patients with stable disease (7.19 ± 5 visits per patient per year). Also, a significant proportion of patients received inhaled corticosteroids as maintenance treatment (59.2%), and the percentage of patients with co-morbidities was remarkable (83.3%). Patients with advanced COPD (stages III-IV) were 2,3 times and 4,2 times more likely to report wheezing or dyspnea as chronic symptoms of the disease [p=0.002 and p=0.003 respectively] compared to patients with stage I-II disease, while high-risk patients (groups C-D) had a 29.1-fold increased risk of severe exacerbations [OR:29.07, 95%CI:8.81-95.92, p=0.000]. 60.4% of patients reported at least one exacerbation during the last year, while 42% of the exacerbations reported were severe. Frequent exacerbations were evident in 19.6% of the sample with exacerbations increasing with disease progression based on stages or groups. Patients with frequent exacerbations were more likely to suffer from advanced disease [p = 0.002] and were 2.5 times more likely to be hospitalized due to exacerbation [OR: 2.5, 95% CI: 1.31-4.78, p = 0.005]. The mean annual direct cost for stable disease was estimated at €1,034.55 per patient, of which €222.94 (21,5%) corresponded to out-of-pocket payments. The key cost driver was pharmaceutical treatment, which reflected almost 71% of the total expenses for the management of stable disease. The mean annual per-patient cost was two to three times higher for those with advanced disease (stages III-IV) compared to those with stages I-II disease [p=0.000] and it was doubled for “high-risk” patients (groups C-D) compared to “low-risk” patients (groups A-B) [p=0.000].Conclusions: There is a high percentage of active smokers, with increased respiratory symptoms and frequent presence of concomitant diseases. The majority of patients suffer from moderate or severe disease, and more than half of them are at high risk. There is increased use of health services by COPD patients at all stages of the disease and many risk factors were found to affect the progression and natural course of the disease. Regardless of disease severity, a significant proportion of patients reports exacerbations, which are appeared to be associated with many clinical factors of the disease. Patients in "high risk" groups appear to have a particularly high risk for hospitalizations due to exacerbations, as they do those who report frequent exacerbations. Moreover, the cost of stable COPD is remarkable with the key cost driver to be pharmaceutical treatment and social insurance funds the key payer for treating COPD patients in Greece. The cost of stable disease is proved proportional to the severity of COPD and it is doubled in patients of high-risk groups.Keywords: stable COPD, risk factors, COPD exacerbations, direct cost, GOLD stages, GOLD groups
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stafyla, Eirini
- Σταφυλά, Ειρήνη
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42499